Next-generation CAR-T cells for glioblastoma targeting tumor microenvironment

Overview

This advanced CAR-T cell therapy is designed to target the challenging tumor microenvironment (TME) of glioblastoma multiforme (GBM), a highly aggressive brain tumor. By engineering CAR-T cells to secrete specific immunomodulatory cytokines, such as IL-12, IFN-γ, TNF-α, and GM-CSF, directly within the TME, the therapy aims to reprogram suppressive myeloid cells and alleviate immunosuppression. Additionally, gene edits are incorporated to prevent T cell exhaustion, thus sustaining CAR-T cell activity and improving their ability to eliminate GBM.

Technical specifications

• Cytokine Secretion: Engineered CAR-T cells secrete cytokines including IL-12, IFN-γ, TNF-α, and GM-CSF to activate anti-tumor macrophages and inhibit suppressive myeloid cells.
• Gene Editing: Utilizes CRISPR/Cas9 technology to identify and knockout genes that cause T cell exhaustion during continuous tumor antigen exposure.
• Validation Methods: In vitro co-culture systems and in vivo mouse models are used to assess CAR expression, cytokine secretion, and TME modulation.

Technology readiness level

This technology is currently at Technology Readiness Level 3, indicating it has been validated in controlled laboratory settings with ongoing efforts to optimize and validate in pre-clinical models.